Mocertatug rezetecan clinical trials
Also written HS-20089.
How each study uses mocertatug rezetecan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the mocertatug rezetecan studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2026 (6)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 1
GlaxoSmithKline (6) · Hansoh BioMedical R&D Company (3) · QuantumLeap Healthcare Collaborative (1) · Jiangsu Hansoh Pharmaceutical Co., Ltd. (1) · Shanghai Hansoh Biomedical Co., Ltd (1)
Often tested with
Tested in the same studies.
Bevacizumab (1) · Trastuzumab (1) · Ganitumab (1) · Ado-Trastuzumab Emtansine (1) · Pertuzumab (1) · STA 9090 (1) · Veliparib (1) · Neratinib (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 1 in phase 3
Studies that test mocertatug rezetecan, phase 3 first.
- Mar 2027HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian CancerPhase 3 · Hansoh BioMedical R&D Company
- Sep 2027A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)Phase 1 · GlaxoSmithKline
Studies
Open first, then newest update. How each study uses mocertatug rezetecan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)RecruitingPhase 3GlaxoSmithKlineNCT07286331Written as Mocertatug rezetecan
- Mo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03]RecruitingPhase 3GlaxoSmithKlineNCT07694427Written as Mocertatug rezetecan
- A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02)RecruitingPhase 3GlaxoSmithKlineNCT07684599Written as Mocertatug rezetecan
- A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)RecruitingPhase 3GlaxoSmithKlineNCT07286266Written as Mocertatug rezetecan
- A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02)RecruitingPhase 3GlaxoSmithKlineNCT07684612Written as Mocertatug rezetecan (Mo-Rez)
- Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian CancerNot yet recruitingPhase 3Hansoh BioMedical R&D CompanyNCT07821606Written as HS-20089+Bevacizumab
- A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)RecruitingPhase 1GlaxoSmithKlineNCT06431594Written as Mocertatug rezetecan
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingPhase 2QuantumLeap Healthcare CollaborativeNCT01042379Written as GSK 5733584
- HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian CancerRecruitingPhase 3Hansoh BioMedical R&D CompanyNCT06855069Written as HS-20089
- HS-10502 Combination Treatment in Patients With Advanced Solid TumorsRecruitingPhase 1Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT06769425Written as HS-10502 + HS-20089
- HS-20089 in Patients With Ovarian Cancer and Endometrial CancerRecruitingPhase 2Hansoh BioMedical R&D CompanyNCT06014190Written as HS-20089
- A Study of HS-20089 in Patients With Advanced Solid TumorsRecruitingPhase 1Shanghai Hansoh Biomedical Co., LtdNCT05263479Written as HS-20089 (Phase Ia:Dose escalation )
Given beside what is tested · 1 — mocertatug rezetecan is usual care or a partner of the new treatment
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
Codes
What other systems call mocertatug rezetecan · ClinicalTrials.gg INT015483
- UNII (FDA) 7K6VKK6DP4MOCERTATUG REZETECANOne source FDA
- NCI Thesaurus C210991Mocertatug RezetecanOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 7K6VKK6DP4 | MOCERTATUG REZETECAN | One source FDA |
| NCI Thesaurus | C210991 | Mocertatug Rezetecan | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.